secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2026-08-24T11:00:28+00:00
Accession:  0001104659-26-099900
Event type: debt
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel extends debt repayment deadline to Aug 28, 2026 via Thirteenth Amendment
--------------------------------------------------------------------------------

- Thirteenth Amendment dated Aug 21, 2026 extends deadline from Aug 21 to Aug 28, 2026 for definitive agreements.
- Company must enter transactions for full repayment of all obligations or alternative capital solutions acceptable to lenders.
- Obligors must consider lender comments on regulatory processes involving material assets through Aug 28, 2026.
- All other Credit Agreement terms remain in effect; no waiver of lender rights or remedies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926099900/0001104659-26-099900-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465926099900/tm2623861d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-099900

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer